You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 24, 2024

Details for Patent: 8,680,144


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 8,680,144 protect, and when does it expire?

Patent 8,680,144 protects VASCEPA and is included in one NDA.

This patent has forty patent family members in fifteen countries.

Summary for Patent: 8,680,144
Title:Methods of treating mixed dyslipidemia
Abstract: The present disclosure relates to, inter alia, methods of treating mixed dyslipidemia with ethyl eicosapentaenoate.
Inventor(s): Osterloh; Ian (Kent, GB), Wicker; Pierre (Mystic, CT), Braeckman; Rene (Richboro, PA), Soni; Paresh (Mystic, CT), Manku; Mehar (Birmingham, GB)
Assignee: Amarin Pharmaceuticals Ireland Limited (Dublin, IE)
Application Number:13/898,457
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,680,144
Patent Claim Types:
see list of patent claims
Use; Dosage form;
Patent landscape, scope, and claims:

Analyzing the Scope and Claims of United States Patent 8,680,144

Introduction

United States Patent 8,680,144, titled "Methods of treating mixed dyslipidemia," is a patent that outlines specific methods for treating a condition characterized by abnormal levels of lipids in the blood. This analysis will delve into the scope, claims, and the broader patent landscape surrounding this patent.

Patent Overview

Publication Number and Authority The patent, numbered US8680144B2, was granted by the United States Patent and Trademark Office (USPTO)[4].

Scope of the Patent

The scope of a patent is defined by its claims, which are the legally binding descriptions of the invention. Here, we will examine the key aspects that define the scope of this patent.

Claim Structure

The patent includes multiple claims, each of which describes a specific aspect of the invention. These claims can be categorized into independent and dependent claims. Independent claims stand alone and define the invention, while dependent claims build upon the independent claims and provide additional details or limitations[3].

Independent Claim Length and Count

Research suggests that the length and count of independent claims can be metrics for measuring patent scope. Generally, narrower claims with fewer words and fewer independent claims are associated with a higher probability of grant and a shorter examination process[3].

Claims Analysis

Independent Claims

The independent claims in US8680144B2 describe methods of treating mixed dyslipidemia using ethyl eicosapentaenoate. For example, Claim 1 might read:

"A method of treating mixed dyslipidemia in a patient, comprising administering to the patient a pharmaceutical composition comprising ethyl eicosapentaenoate."

Dependent Claims

Dependent claims further specify the conditions, dosages, or other parameters of the treatment method. For instance:

"The method of claim 1, wherein the pharmaceutical composition is administered orally."

Patent Claims and Scope

The claims in this patent are designed to be specific enough to protect the invention while being broad enough to cover various aspects of the treatment method.

Claim Breadth

The breadth of the claims is crucial as it determines the extent of protection granted by the patent. Broader claims may cover more variations of the invention but are also more likely to face challenges during the examination process. In contrast, narrower claims are more likely to be granted but offer less protection[3].

Patent Landscape

Prior Art and Related Patents

The patent landscape includes prior art and related patents that deal with similar treatments or compounds. The prior art keywords listed in the patent, such as "pat," "per," "epa," "composition," and "acid," indicate that the invention builds upon existing knowledge in the field of lipid treatment and omega-3 fatty acid therapies[4].

International and National Patent Offices

The patent is part of a global patent landscape, with similar patents potentially filed in other jurisdictions. The USPTO's Patent Public Search database, along with international databases like PATENTSCOPE, can be used to search for related patents and applications worldwide[1].

Inventorship and Ownership

Determining Inventorship

US patent law requires that only the true and only inventors be listed on the patent application. This involves a two-step process: conception of the idea and reduction of the idea to practice. Ensuring correct inventorship is crucial to avoid legal disputes and maintain the validity of the patent[5].

Examination Process

The examination process for this patent would have involved a thorough review by the USPTO to ensure that the claims are novel, non-obvious, and meet the requirements for patentability. The Cooperative Patent Classification (CPC) system would have been used to classify the patent and compare it with existing patents in the same class[1].

Practical Implications

Licensing and Litigation

The scope and claims of the patent have significant implications for licensing and litigation. Broader claims may lead to increased licensing and litigation costs, as they can be more contentious. Narrower claims, while offering less protection, may reduce these costs and facilitate smoother licensing agreements[3].

Market Impact

The patent's scope affects its market impact. A patent with broad claims can potentially block competitors from entering the market, while narrower claims may allow for more competition. In the context of treating mixed dyslipidemia, this patent could influence the development of new treatments and the market share of existing treatments.

Key Takeaways

  • Scope Definition: The scope of US8680144B2 is defined by its claims, which describe methods of treating mixed dyslipidemia using ethyl eicosapentaenoate.
  • Claim Structure: The patent includes independent and dependent claims, with narrower claims generally associated with a higher probability of grant.
  • Patent Landscape: The patent is part of a global landscape, with prior art and related patents influencing its validity and scope.
  • Inventorship: Correct determination of inventorship is crucial for the patent's validity.
  • Examination Process: The USPTO's examination process ensures the patent meets the requirements for novelty, non-obviousness, and patentability.

FAQs

Q: What is the main subject matter of US Patent 8,680,144? A: The main subject matter is methods of treating mixed dyslipidemia using ethyl eicosapentaenoate.

Q: How are the claims structured in this patent? A: The claims include independent claims that define the invention and dependent claims that provide additional details or limitations.

Q: What is the significance of claim breadth in patent scope? A: Claim breadth determines the extent of protection granted by the patent, with broader claims offering more protection but facing more challenges during examination.

Q: How does the USPTO determine the validity of a patent? A: The USPTO uses a thorough examination process to ensure the claims are novel, non-obvious, and meet the requirements for patentability.

Q: Why is correct inventorship important for a patent? A: Correct inventorship is crucial to avoid legal disputes and maintain the validity of the patent.

Sources

  1. Clemson University Libraries. Advanced Patent Searching: Overview. Clemson.libguides.com.
  2. USA.gov. U.S. Patent and Trademark Office (USPTO). Usa.gov.
  3. SSRN. Patent Claims and Patent Scope. Papers.ssrn.com.
  4. Google Patents. US8680144B2 - Methods of treating mixed dyslipidemia. Patents.google.com.
  5. Oregon State University. Determining Inventorship for US Patent Applications. Agsci.oregonstate.edu.

More… ↓

⤷  Subscribe


Drugs Protected by US Patent 8,680,144

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Amarin Pharms VASCEPA icosapent ethyl CAPSULE;ORAL 202057-001 Jul 26, 2012 AB RX Yes Yes 8,680,144 ⤷  Subscribe USE OF VASCEPA TO TREAT MIXED HYPERTRIGLYCERIDEMIA IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE (TG) LEVELS (>= 150 MG/DL) AND ON STATIN THERAPY ⤷  Subscribe
Amarin Pharms VASCEPA icosapent ethyl CAPSULE;ORAL 202057-002 Feb 16, 2017 AB RX Yes No 8,680,144 ⤷  Subscribe USE OF VASCEPA TO TREAT MIXED HYPERTRIGLYCERIDEMIA IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE (TG) LEVELS (>= 150 MG/DL) AND ON STATIN THERAPY ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.